{"id":"W2366481835","doi":"10.1111/bjh.14125","title":"A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis","year":2016,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"Takeda Oncology","keywords":"Ixazomib; Medicine; Multiple myeloma; Renal function; Pharmacokinetics; Urology; End stage renal disease; Adverse effect; Internal medicine; Gastroenterology; Pharmacology; Proteasome inhibitor; Hemodialysis; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003608882,0.0002039216,0.0009059998,0.000307836,0.00008091137,0.00002285499,0.0001001033,0.00005851492,0.000132284],"category_scores_gemma":[0.000384039,0.0001345534,0.0000700774,0.0001686929,0.0002371465,0.0002083764,0.0001098603,0.0002155407,7.095215e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009566955,"about_ca_system_score_gemma":0.0001825691,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001522465,"about_ca_topic_score_gemma":0.0005809789,"domain_scores_codex":[0.9977235,0.0002724295,0.0007944684,0.000297131,0.0005184454,0.0003940166],"domain_scores_gemma":[0.9983963,0.0002295532,0.0003949784,0.0001648855,0.0002716033,0.0005427151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04332328,0.006816638,0.8057331,0.0001550474,0.0007077709,0.05346745,0.0002817406,0.000006083233,0.0003261593,0.000001622128,0.00008835382,0.08909275],"study_design_scores_gemma":[0.157963,0.007238457,0.8229841,0.001098641,0.0004202642,0.00929147,0.0002252119,0.000152178,0.0003540062,0.00001054446,0.00009037904,0.0001717028],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982251,0.0004359708,0.000115183,0.0001915202,0.00003231789,0.0008236329,0.0001608479,0.000007211179,0.000008234199],"genre_scores_gemma":[0.99856,0.0004239435,0.0008431769,0.00002796651,0.00003029772,0.00001598869,0.00001326273,0.0000239921,0.00006142762],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1146397,"threshold_uncertainty_score":0.5486929,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01956175581877296,"score_gpt":0.3082482007602953,"score_spread":0.2886864449415223,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}